DAVID GRAHAM to Cyclooxygenase Inhibitors
This is a "connection" page, showing publications DAVID GRAHAM has written about Cyclooxygenase Inhibitors.
Connection Strength
0.929
-
NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology. 2008 Apr; 134(4):1240-6.
Score: 0.293
-
Is the use of COX-2 inhibitors in gastroenterology cost-effective? Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):60-1.
Score: 0.232
-
Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol. 2001 Oct; 15(5):775-85.
Score: 0.187
-
NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opin Pharmacother. 2005 Dec; 6(15):2681-9.
Score: 0.062
-
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med. 2002 Dec 26; 347(26):2162-4.
Score: 0.051
-
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24; 282(20):1921-8.
Score: 0.041
-
Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol. 1996 Oct; 91(10):2080-6.
Score: 0.033
-
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009 Apr; 157(4):606-12.
Score: 0.019
-
Nonsteroidal anti-inflammatory drug use in dentistry: gastrointestinal implications. Gen Dent. 1999 Nov-Dec; 47(6):590-6; quiz 597-8.
Score: 0.010